ReviewCancer chemotherapy and pharmacology2023
Mechanism of cisplatin resistance in gastric cancer and associated microRNAs.
Review in Cancer chemotherapy and pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Exosomal circVANGL1 promotes cisplatin resistance in osteosarcoma cells by regulating the miR-145-5p/E2F3 axis.Discover oncology · 2026Article
- Characteristics, treatment, and outcome of recurrent gastro-oesophageal adeno-carcinoma after perioperative chemotherapy and radical resection.Acta oncologica (Stockholm, Sweden) · 2026Article
- Cisplatin as a Xenobiotic Agent: Molecular Mechanisms of Actions and Clinical Applications in Oncology.Journal of xenobiotics · 2026Review
- Mutation-Immune Crosstalk Contextualizes CAF-Associated ARPC1A Programs and Cisplatin Response in Gastric Cancer.Human mutation · 2026Article
- Multi-omics integration and Mendelian randomization elucidate the PARP16-UPR axis driving chemoresistancein gastric cancer.Frontiers in oncology · 2026Article
- Multi-omics integration and Mendelian randomization reveal the mechanisms and experimental validation of curcumin targeting the RXRA-PI3K/AKT axis to enhance cisplatin sensitivity in gastric cancer.Frontiers in oncology · 2026Article
- MiR-668-3p in M2 macrophage-derived exosomes activates autophagy through the ETS1/EGFR axis and promotes cisplatin resistance in gastric cancer.Cancer cell international · 2025Article
- Comparative Binding Affinities of Platinum-Based Drugs toward Purine Alkaloids and Nucleobases.ACS omega · 2025Article
- A dual-functional cobalt ferrite nanocomplex for targeted cisplatin prodrug delivery and MALAT1 gene silencing in gastric cancer cells.Scientific reports · 2025Article
- The Stem Cell Transcription Factor OCT4 Silences Target DNA Methyltransferase 1 to Strengthen DNA Damage Response in Cisplatin-Treated Gastric Cancer Cells.Biotechnology and applied biochemistry · 2025Article
- HSP90/PUS7/THUMPD1 promotes metastasis and cisplatin resistance in gastric cancer cells.Scientific reports · 2025Article
- Patient-derived tumor xenograft animal model of gastric cancer in precision chemotherapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the TP53/SLC7A11/ALOX12 axis.Hereditas · 2025Article
- A state-of-the-art view: G-quadruplex-targeting for platinum complexes' treatment of tumors.RSC chemical biology · 2025Review
- Exosomal miR‑3681‑3p from M2‑polarized macrophages confers cisplatin resistance to gastric cancer cells by targeting MLH1.Molecular medicine reports · 2025Article
- Synergistic effects of dihydroartemisinin and cisplatin on inducing ferroptosis in gastric cancer through GPX4 inhibition.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Miltirone enhances the chemosensitivity of gastric cancer cells to cisplatin by suppressing the PI3K/AKT signaling pathway.Frontiers in pharmacology · 2025Article
- Advances in Expression Regulation, Molecular Targeting Mechanisms, and Therapeutic Applications of the Let-7 MicroRNA Family in Gastric Cancer.Oncology research · 2025Review
- Ginsenoside RG3 Synergizes With STING Agonist to Reverse Cisplatin Resistance in Gastric Cancer.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is a common malignant tumor with high morbidity and mortality rates that seriously affects human health worldwide. Although surgery is currently the preferred clinical treatment for GC, chemotherapy remains the first choice for perioperative treatment, adjuvant therapy, and palliative care for patients with advanced GC. Cisplatin (DDP) is an antineoplastic agent that has been used clinically for decades, and it is the first-line chemotherapy for many solid tumors. However, the therapeutic efficacy of DDP is often limited by resistance and the complexity of its resistance mechanisms, which involve multiple proteins and signaling pathways. It is well documented that a variety of microRNAs (miRNAs) differentially expressed in DDP-resistant GC cells play important roles in regulating or reversing DDP resistance via various pathways. In this review, we first provide an introduction to the cytotoxicity and major resistance mechanisms of DDP in GC and then discuss the role and mechanism of miRNAs in regulating the DDP resistance process in GC cells. This work demonstrates the potential of relevant miRNAs to become diagnostic and prognostic biomarkers for gastric cancer and targets of action to enhance chemosensitivity and provides directions for future research.
Indexed as
Identifiers
37535106What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.